Health Care • Biotechnology: Pharmaceutical Preparations
$146.15 ▼ -5.43
(-3.58%)
MKT CAP: $2.11B • VOL: 293.1K
52W L $72 52W H $161
ROARABLE / RQD
D • 45/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$123
MEDIAN
$164
MEAN
$167
HIGH
$199
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PVLA TAPE
PVLA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $176.84 | $168.07 | 2025-02-14 | $133.00 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $184.15 | $172.46 | 2025-02-06 | $137.38 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $166.61 | $160.77 | 2025-01-29 | $140.30 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $149.07 | — | 2025-01-17 | $143.23 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $128.61 | $138.84 | 2025-01-09 | $130.07 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $173.92 | $152.00 | 2024-12-18 | $127.15 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $141.77 | $147.61 | 2024-12-04 | $135.92 | -4.3% | 48% | C |